Loss of STK11 function or mutations in LKB1 have been identified in 10%–20% of NSCLC and are believed to confer inferior survival outcomes and relative ICI resistance in advanced NSCLC when compared to wild-type tumours (117, 118). This evidence concerns the gene STK11 and neoplasm.